🏛️ Verified NIH Record • Updated 2026-08-20
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma (NCT05034536)
A Phase II Study of PD-1 Blockade With or Without LAG-3 Inhibition in Combination With Infliximab for the Treatment of Metastatic Melanoma and Prevention of Adverse Events
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Massachusetts General Hospital
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this research is to test the safety and effectiveness of the investigational combination of anti-Programmed Death (PD)-1 antibody therapy with or without LAG-3 inhibition (pembrolizumab or nivolumab+relatlimab) and infliximab in treating metastatic melanoma.
Who can join: Review the eligibility criteria below.
Location: Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Melanoma
- Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma — Boston, Massachusetts
- IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) — Orange City, Florida
- Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies — Jacksonville, Florida
- Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma — Houston, Texas
- Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients — Louisville, Kentucky
- Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. — Portland, Oregon
Explore by condition: All Metastatic Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.